EHP-101 has shown promise for the modulation of relevant multiple sclerosis targets, having PPARγ and CB2-mediated anti-inflammatory activity, and the potential to enhance remyelination.
A drug policy researcher is proposing a suite of changes to overhaul the Multi-Criteria Drug Harm Scale, which informs drug policies across Europe.
The project will investigate the pain relief properties of CBD oil by exploring its mechanism of action in pain and associated depression and anxiety.
Anandia is the Canadian leader in independent third-party testing and was awarded "Top Testing Lab" at the 2017 Lift Canadian Cannabis Awards.
With only a patchwork of state cannabis laws currently in existence, these new recommendations offer a unified federal framework to help optimize the care of patients across the country.
According to statistics provided by California’s Bureau of Cannabis Control, 20% of all cannabis products analyzed by August 6, 2018, received a failed certificate of analysis.
The media is claiming that long-term cannabis use could result in damage to the human brain based on findings from a research study that used neither cannabis or humans.
This is the first time scientists have reported a biological mechanism to explain why some marijuana users have reported beneficial effects from cannabis on intestine inflammation conditions such as ulcerative colitis and Crohn's disease.
The extraction processes provide highly-efficient methods to obtain cannabinoids and other desired compounds from the cannabis plant at a greater purity than conventional methods.
What's most transformative about this drug approval is that this is the first time the FDA - the governmental arbiter of safe and effective medicine in the United States - has approved any substance derived from the cannabis plant.